StockNews.AI
XERS
StockNews.AI
173 days

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

1. Xeris Biopharma will release Q4 and 2024 financial results on March 6, 2025. 2. The upcoming guidance may influence investor sentiment and stock price.

Earnings
-0.66%Current Return
VS
-1.66%S&P 500
$3.7802/27 07:20 AM EDTEvent Start
$3.75502/28 02:12 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Positive financial results or guidance could boost investor confidence. Historical trends show earnings announcements can significantly sway stock prices.

How important is it?

Earnings announcement is crucial for stock valuation and equities health; positive outcomes can enhance market perception.

Why Short Term?

Effect likely immediate during and after the earnings call. Past results show rapid price movement around earnings announcements.

Related Companies

XERSNDAQAMGNPFE
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webca.

Related News